GIM
REPL icon

Glenmede Investment Management’s Replimune Group REPL Stock Holding History

Glenmede Investment Management’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,650
Closed -$238K – 1558
2025
Q2 		$238K Buy
+25,650
New +$224K ﹤0.01% 1180

Other funds holding REPL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Glenmede Investment Management's REPL Position: Q3 2025 in Review

Glenmede Investment Management sold out of Replimune Group (REPL) in Q3 2025, closing a stake of 25,650 shares — an estimated $238K sold.

Glenmede Investment Management first reported a position in REPL in Q2 2025 and held it in 1 quarter. The position peaked at $238K in Q2 2025. 163 funds tracked by Wall St. Rank hold REPL as of Q3 2025.

  • Glenmede Investment Management reported no remaining Replimune Group position as of Q3 2025 after selling out during the quarter.
  • Glenmede Investment Management sold 25,650 Replimune Group shares in Q3 2025, an estimated $238K.
  • Glenmede Investment Management first reported a position in Replimune Group in Q2 2025 and held it in 1 quarter.
  • Glenmede Investment Management's Replimune Group position peaked at $238K in Q2 2025.
  • 163 funds tracked by Wall St. Rank held Replimune Group as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.